이 보고서는 2016년부터 2024년까지 유전자 편집 관련 제휴 및 라이선스 계약을 조사하여 전체 계약 건수 추이, 금전적 계약 조건, 계약에 적극적인 주요 기업 파악, 계약 문서 디렉토리 등을 정리했습니다.
주요 이점
- 2016년 이후 계약 추이를 파악할 수 있습니다.
- 제휴 및 라이선싱 관련 정보를 열람할 수 있습니다.
- 벤치마크 분석 : 계약의 시장 가치를 파악할 수 있습니다.
- 금융 조건 : 일시금, 마일스톤, 로열티
- 계약 디렉토리 : 기업명(A-Z), 계약 유형, 치료 분야별
- 주요 계약 : 계약금액 기준
- 가장 활발한 계약 기업
- 각 계약의 자산 및 계약 조건 확인
- 계약 문서에 대한 액세스 : 계약 구조에 대한 인사이트
- 실사 : 제안된 계약 조건이 파트너사에 적합한지 여부를 평가합니다.
- 수백 시간의 조사 시간을 절약할 수 있습니다.
계약서 분석을 통해 다음과 같은 실사를 할 수 있습니다.
- 부여 또는 옵션으로 설정된 정확한 권리는 무엇인가?
- 계약에 따라 제휴사에게 실제로 부여되는 혜택은 무엇인가?
- 어떤 독점권이 부여되었는가?
- 계약의 지불 구조는?
- 판매 및 지불은 어떻게 감사되는가?
- 계약기간은 얼마인가요?
- 계약의 주요 조건은 어떻게 정의되는가?
- 지적재산권은 어떻게 취급되고 소유되는가?
- 상용화 책임자는 누구인가?
- 개발, 공급, 제조 책임자는 누구인가?
- 비밀 유지 및 공개는 어떻게 관리되는가?
- 분쟁은 어떻게 해결되는가?
- 어떤 조건으로 계약을 해지할 수 있는가?
- 소유주가 바뀌면 어떻게 되는가?
- 어떤 종류의 서브 라이선스 조항 및 하도급 조항이 합의되었는가?
- 기업은 어떤 정형화된 조항을 요구하는가?
- 파트너와 거래 유형에 따라 달라지는 정형화된 조항은 어떤 것이 있는가?
- 각 기업은 계약법에 대해 어떤 관할권을 주장하고 있는가?
목차
주요 요약
제1장 소개
제2장 유전자 편집 영역 계약 동향
- 유전자 편집 관련 계약 : 연간 추이
- 가장 활발한 유전자 편집 계약자
- 유전자 편집 관련 계약 : 계약 유형별
- 유전자 편집 관련 계약 : 치료 분야별
- 유전자 편집 관련 계약 : 산업 부문별
- 유전자 편집 관련 계약 : 계약 조건
제3장 주요 유전자 편집 계약
제4장 가장 활발한 유전자 편집 계약자
- 가장 활발한 유전자 편집 계약자
- 가장 활발한 유전자 편집 계약 기업 개요
제5장 유전자 편집 계약 : 계약 디렉토리
제6장 유전자 편집 계약 : 기술 유형별
- 계약 디렉토리
- 계약 디렉토리 : 기업(A-Z)별
- 계약 디렉토리 : 계약 유형별
- 계약 디렉토리 : 치료 분야별
- 계약 유형의 정의
- Biopharma Research Ltd에 대해
- 현재 제휴
- 현재 계약
- Current Partnering의 최근 보고서 제목
ksm
Gene Editing Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene editing deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of gene editing deals from 2016 to 2024.
The report provides a detailed understanding and analysis of how and why companies enter gene editing deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 373 gene editing deals announced since 2016 including financial terms where available including links to online deal records of actual gene editing partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of gene editing dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in gene editing dealmaking since 2016.
Chapter 3 provides an overview of the leading gene editing deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in gene editing dealmaking with a brief summary followed by a comprehensive listing of gene editing deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of gene editing deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of gene editing partnering deals signed and announced since Jan 2016. The chapter is organized by specific gene editing technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in gene editing deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Gene Editing Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse gene editing collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report scope
- Gene Editing Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene editing trends and structure of deals entered into by leading biopharma companies worldwide.
Gene Editing Collaboration and Licensing Deals includes:
- Trends in gene editing dealmaking in the biopharma industry
- Directory of gene editing deal records covering pharmaceutical and biotechnology
- The leading gene editing deals by value
- Most active gene editing licensing dealmakers
- Gene Editing Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in gene editing dealmaking
- 2.1. Introduction
- 2.2. Gene editing deals over the years
- 2.3. Most active gene editing dealmakers
- 2.4. Gene editing deals by deal type
- 2.5. Gene editing deals by therapy area
- 2.6. Gene editing deals by industry sector
- 2.7. Deal terms for gene editing deals
- 2.7.1 Gene editing deals headline values
- 2.7.2 Gene editing deal upfront payments
- 2.7.3 Gene editing deal milestone payments
- 2.7.4 Gene editing royalty rates
Chapter 3 - Leading gene editing deals
- 3.1. Introduction
- 3.2. Top gene editing deals by value
Chapter 4 - Most active gene editing dealmakers
- 4.1. Introduction
- 4.2. Most active gene editing dealmakers
- 4.3. Most active gene editing deals company profiles
Chapter 5 - Gene editing contracts dealmaking directory
- 5.1. Introduction
- 5.2. Gene editing contracts dealmaking directory
Chapter 6 - Gene editing dealmaking by technology type
- Deal directory
- Deal directory - Gene editing deals by company A-Z
- Deal directory - Gene editing deals by deal type
- Deal directory - Gene editing deals by therapy area
- Deal type definitions
- About Biopharma Research Ltd
- Current Partnering
- Current Agreements
- Recent report titles from Current Partnering
Table of figures
- Figure 1: Gene editing deals since 2016
- Figure 2: Active gene editing dealmaking activity - 2016 - 2024
- Figure 3: Gene editing deals by deal type since 2016
- Figure 4: Gene editing deals by therapy area since 2016
- Figure 5: Gene editing deals by industry sector since 2016
- Figure 6: Gene editing deals with a headline value
- Figure 7: Gene editing deals with an upfront value
- Figure 8: Gene editing deals with a milestone value
- Figure 9: Gene editing deals with a royalty rate value
- Figure 10: Top gene editing deals by value since 2016
- Figure 11: Most active gene editing dealmakers 2016 - 2024
- Figure 12: Gene editing deals by technology type since 2016
